GlassScriptPhysician profile
Ramses Ribot
NPI 1851547764
$6,965.32
in general payments reported to CMS, 2019-2025
10 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,131 · 2020: $51.88 · 2021: $36.63 · 2023: $369 · 2024: $757 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $3,542.01 | 2019 | |
| Medtronic USA, INC. | $1,466.73 | 2019-2020 | |
| Neuropace, INC. | $562.70 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $492.01 | 2023-2025 | |
| Ucb, INC. | $472.18 | 2021-2025 | Fintepla, Briviact |
| Livanova USA, INC. | $194.14 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $145.71 | 2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $49.09 | 2019 | |
| Eisai INC. | $25.25 | 2019 | |
| Biogen, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramses Ribot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.